|
Leukopenia
|
0.020 |
Biomarker
|
disease |
BEFREE |
The MTD of selumetinib was 75 mg BID in combination with either docetaxel (two dose-limiting toxicity [DLT] events: neutropenia with fever, and thrombocytopenia) or dacarbazine (one DLT event: thrombocytopenia).
|
28264648 |
2017 |
|
Leukopenia
|
0.020 |
Biomarker
|
disease |
BEFREE |
In the phase 1b study (n = 28), 1 patient treated with ganitumab experienced a DLT (Grade 4 neutropenia/thrombocytopenia lasting ≥ 7 days).
|
28601388 |
2017 |
|
Neutropenia
|
0.020 |
Biomarker
|
disease |
BEFREE |
The MTD of selumetinib was 75 mg BID in combination with either docetaxel (two dose-limiting toxicity [DLT] events: neutropenia with fever, and thrombocytopenia) or dacarbazine (one DLT event: thrombocytopenia).
|
28264648 |
2017 |
|
Neutropenia
|
0.020 |
Biomarker
|
disease |
BEFREE |
In the phase 1b study (n = 28), 1 patient treated with ganitumab experienced a DLT (Grade 4 neutropenia/thrombocytopenia lasting ≥ 7 days).
|
28601388 |
2017 |
|
Stomatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
One DLT occurred (Grade 3 decreased appetite and stomatitis [Part 2]).
|
28973403 |
2017 |
|
Joint tenderness
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Tender joint count (TJC) is included in Composite Disease Activity Scores (CDAS) (DAS28/CDAI/SDAI).
|
30474932 |
2020 |
|
Fatigue
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
For the safety analysis (n = 20), treatment-related grade 1 adverse events included fatigue (n = 6), chills (n = 2), and headache (n = 1), with no organ damage and no DLT.
|
30705966 |
2019 |
|
Thrombocytopenia
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Bronchopulmonary hemorrhage from Grade 3 thrombocytopenia (<i>N</i> = 1) was a DLT.
|
30733229 |
2019 |
|
Joint tenderness
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In male, but not female, ueRA patients Th2 cells showed a positive association with disease activity and correlated significantly with DAS28-ESR, CDAI, and swollen and tender joint counts.
|
30029616 |
2018 |
|
Iron Overload
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Congenital dyserythropoietic anemia type I (CDA1) can present in utero with hydrops fetalis, but more often it presents in childhood or adulthood with moderate macrocytic anemia, jaundice, and progressive iron-overload.
|
29599085 |
2018 |
|
Thrombocytopenia
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In the phase 1b study (n = 28), 1 patient treated with ganitumab experienced a DLT (Grade 4 neutropenia/thrombocytopenia lasting ≥ 7 days).
|
28601388 |
2017 |
|
Thrombocytopenia
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
The MTD of selumetinib was 75 mg BID in combination with either docetaxel (two dose-limiting toxicity [DLT] events: neutropenia with fever, and thrombocytopenia) or dacarbazine (one DLT event: thrombocytopenia).
|
28264648 |
2017 |
|
Secondary hemochromatosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Congenital dyserythropoietic anemia type I (CDAI) is a rare autosomal recessive disease characterized by macrocytic anemia, ineffective erythropoiesis, and secondary hemochromatosis.
|
27206021 |
2017 |
|
Joint tenderness
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
AIx correlated with time-averaged tender joint count (r = 0.37, P = .008), CDAI (r = 0.36, P = .01), HAQ-II (r = 0.36, P = .01), swollen joint count (r = 0.36, P = .10), patient global assessment (r = 0.33, P = .02), physician global assessment (r = 0.35, P = .01), and pain score (r = 0.38, P = .007).
|
27988813 |
2017 |
|
Fatigue
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
Moderate/severe toxicities included fatigue (DLT at veliparib 400mg BID), diarrhea, and thrombocytopenia.
|
26848151 |
2016 |
|
Fatigue
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Two of 6 patients in cohort -1 had a DLT (grade 3 pulmonary embolism and grade 3 fatigue); thus, the study was terminated.
|
26149476 |
2015 |
|
Secondary hemochromatosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Congenital dyserythropoietic anemia type I is an inherited autosomal recessive macrocytic anemia associated with ineffective erythropoiesis and the development of secondary hemochromatosis.
|
19336738 |
2009 |
|
Iron Overload
|
0.030 |
Biomarker
|
disease |
BEFREE |
Congenital dyserythropoietic anemia type I (CDA I) is a rare autosomal recessive disorder with ineffective erythropoiesis and iron overloading.
|
16141353 |
2006 |
|
Iron Overload
|
0.030 |
Biomarker
|
disease |
BEFREE |
Congenital dyserythropoietic anemia type I (CDA I) is a rare autosomal recessive disorder with ineffective erythropoiesis, characteristic morphological abnormalities of erythroblasts, and iron overloading.
|
16767397 |
2006 |
|
Secondary hemochromatosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Therapeutic measures include interferon-alpha for CDA I, splenectomy for CDA II, and iron depletion for all individuals at risk for secondary hemochromatosis.
|
15278299 |
2004 |
|
Anemia, Macrocytic
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Congenital dyserythropoietic anemia type I (CDA1) can present in utero with hydrops fetalis, but more often it presents in childhood or adulthood with moderate macrocytic anemia, jaundice, and progressive iron-overload.
|
29599085 |
2018 |
|
Anemia, Macrocytic
|
0.040 |
Biomarker
|
disease |
BEFREE |
Congenital dyserythropoietic anemia type I (CDAI) is a rare autosomal recessive disease characterized by macrocytic anemia, ineffective erythropoiesis, and secondary hemochromatosis.
|
27206021 |
2017 |
|
Anemia, Macrocytic
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Congenital dyserythropoietic anemia type I is an inherited autosomal recessive macrocytic anemia associated with ineffective erythropoiesis and the development of secondary hemochromatosis.
|
19336738 |
2009 |
|
Anemia, Macrocytic
|
0.040 |
Biomarker
|
disease |
BEFREE |
Congenital dyserythropoietic anemia type I is a rare inherited bone marrow disorder characterised by macrocytic anemia with pathognomonic morphological ultrastructural features in erythroid precursors.
|
9255198 |
1997 |
|
Rheumatoid Arthritis
|
0.070 |
Biomarker
|
disease |
BEFREE |
In routine care across 7 European countries, the adjusted drug retention, adjusted CDAI over time and attrition-corrected response proportion for RA patients were similar for bio-naïve patients if treated with TNFi-combo, TCZ-combo or TCZ-mono.
|
31280937 |
2020 |